Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Ticagrelor Market from 2024 to 2025?

The market size of ticagrelor has seen robust growth in the past years. It’s projected to escalate from $1.79 billion in 2024 to $1.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. The growth observed during the historic period is credited to the escalating prevalence of cardiovascular diseases, the increase in the aging population, heightened awareness of heart health, the expansion of pharmaceutical research, and the growing occurrence of acute coronary syndrome.

What Is the Projected Market Size of the Ticagrelor Market?

In the upcoming years, the ticagrelor market is projected to experience robust growth. The market is predicted to increase to $2.57 billion by 2029, with an annual compound growth rate (CAGR) of 7.4%. This anticipated growth over the forecast period is due to the rising incorporation of personalized medicine, increased healthcare spending, a growing demand for less invasive treatments, a heightened emphasis on preventive cardiology, and government-led initiatives for heart care. Significant trends during the forecast period are expected to be the advancement of personalized medicine, the emergence of generic ticagrelor, the application of artificial intelligence in drug creation, the inception of next-gen antiplatelet medications, and an emphasis on patient adherence through fixed-dose combinations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24726&type=smp

Who are the Major Competitors in the Ticagrelor Market Outlook?

Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.

What Is Fueling Growth in the Ticagrelor Market?

The surge in cardiovascular diseases is anticipated to bolster the ticagrelor market’s growth. Cardiovascular diseases embody a set of disorders impacting the heart and circulatory system, like coronary heart disease, heart failure, stroke, and hypertension. The rise in these diseases is predominantly blamed on poor nutrition, with diets high in saturated fats, trans fats, added sugars, and sodium leading to increased blood pressure, obesity, and cholesterol levels – significant risks for heart illnesses. Ticagrelor plays a crucial role in combating these diseases by inhibiting platelet aggregation, thereby decreasing blood clot occurrences. It enhances patient prognosis by reducing the likelihood of heart attacks and strokes, particularly in individuals at higher risk. For instance, the American Heart Association reported in January 2024 that the age-adjusted death rate due to cardiovascular disease climbed to 233.3 per 100,000 in 2022, a 4.0% rise from 224.4 per 100,000 in 2021. Consequently, the growing incidence of cardiovascular diseases is fueling ticagrelor market expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24726&type=smp

Which Ticagrelor Market Segments Are Growing the Fastest?

The ticagrelor market covered in this report is segmented –

1) By Type: 90 mg Tablet, 60 mg Tablet

2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications

5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users

Subsegments:

1) By 90 Mg Tablet: Standard 90 Mg Ticagrelor Tablet, Extended-Release 90 Mg Ticagrelor Tablet

2) By 60 Mg Tablet: Standard 60 Mg Ticagrelor Tablet, Extended-Release 60 Mg Ticagrelor Tablet

Which Industry Trends Are Shaping the Future of the Ticagrelor Market?

Key players in the ticagrelor market are zeroing in on securing regulatory permissions to broaden their product range, enhance market reach and fortify their competitive standing. Such regulatory permissions imply formal approval from government bodies to distribute and sell a particular product, after confirming that it meets safety, efficacy, and quality parameters. In a case in point, Alembic Pharmaceuticals Ltd., a pharmaceutical firm based in India, got the go-ahead for an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg, in addition to a tentative approval for the 60 mg dosage, in May 2025. These tablets, which curb the probability of cardiovascular episodes by interrupting the process of platelet aggregation, help prevent formation of blood clots.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ticagrelor-global-market-report

Which Countries Are Leading the Ticagrelor Market?

North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24726

This Report Delivers Insight On:

1. How big is the ticagrelor market, and how is it changing globally?

2. Who are the major companies in the ticagrelor market, and how are they performing?

3. What are the key opportunities and risks in the ticagrelor market right now?

4. Which products or customer segments are growing the most in the ticagrelor market?

5. What factors are helping or slowing down the growth of the ticagrelor market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model